Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadeem A Sheikh

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer Immunology Research|September 6, 2014
A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-TDouglas G McNeel, Thomas A Gardner, Celestia S Higano, et al.
Journal of the National Cancer Institute|March 8, 2020
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-TRavi A Madan, Emmanuel S Antonarakis, Charles G Drake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2015
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate CancerEric J Small, Raymond S Lance, Thomas A Gardner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE TrialsEmmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2012
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerNadeem A Sheikh, Daniel Petrylak, Philip W Kantoff, et al.
Journal of the National Cancer Institute|September 27, 2014
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancerLawrence Fong, Peter Carroll, Vivian Weinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2018
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall SurvivalEmmanuel S Antonarakis, Eric J Small, Daniel P Petrylak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized TrialEmmanuel S Antonarakis, Adam S Kibel, Evan Y Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical OutcomeDebraj GuhaThakurta, Nadeem A Sheikh, Li-Qun Fan, et al.
Prostate Cancer and Prostatic Diseases|March 1, 2020
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registryOliver Sartor, Andrew J Armstrong, Chiledum Ahaghotu, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Immunology Research|September 6, 2014
A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-TDouglas G McNeel, Thomas A Gardner, Celestia S Higano, et al.
Journal of the National Cancer Institute|March 8, 2020
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-TRavi A Madan, Emmanuel S Antonarakis, Charles G Drake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2015
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate CancerEric J Small, Raymond S Lance, Thomas A Gardner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE TrialsEmmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2012
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerNadeem A Sheikh, Daniel Petrylak, Philip W Kantoff, et al.
Journal of the National Cancer Institute|September 27, 2014
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancerLawrence Fong, Peter Carroll, Vivian Weinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2018
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall SurvivalEmmanuel S Antonarakis, Eric J Small, Daniel P Petrylak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized TrialEmmanuel S Antonarakis, Adam S Kibel, Evan Y Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical OutcomeDebraj GuhaThakurta, Nadeem A Sheikh, Li-Qun Fan, et al.
Prostate Cancer and Prostatic Diseases|March 1, 2020
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registryOliver Sartor, Andrew J Armstrong, Chiledum Ahaghotu, et al.
Pageof 2